ETS Therapy List

ETS Specialty Services

Current Gene and Cell Therapy List*

Provided by Emerging Therapy Solutions (ETS)

Updated: February 16, 2021

Emerging Therapy Solutions provides access to our “ETS Specialty Services”, which is access to contracted hospitals or facilities that offer condition-specific evaluations necessary to determine the appropriate procedures and therapies, and the associated services and supplies, that are required for the treatment of complex conditions. Below is a list of the US Food and Drug Administration (FDA) approved cell and gene therapies as well as the conditions pertinent to those therapies that are included in the “ETS Specialty Services.” Please see your plan document for your specific therapy coverage.

NOTE: This list is subject to change with the availability of new therapies and medical innovations.

 

Service Type (Listed by Therapy Name)

Chimeric Antigen Receptor (CAR) T-cell Therapies

 

Breyanzi® (lisocabtagene maraleucel)1

For relapsed or refractory large B-cell lymphoma including diffuse large B-cell lymphoma, and follicular lymphoma grade 3B

 

Kymriah® (tisagenlecleucel)2

For relapsed or refractory acute lymphoblastic leukemia up to age 25, and for adult relapsed or refractory diffuse large B-cell lymphoma

 

Tecartus™ (brexucabtagene autoleucel)3

For relapsed or refractory mantle cell lymphoma

 

Yescarta® (axicabtagene ciloleucel)4

For relapsed or refractory B-cell non-Hodgkin’s lymphoma

Gene Therapies

 

Luxturna® (voretigene neparvovec)5

For biallelic RPE65 gene mutation

 

Zolgensma® (onasemnogene abeparvovec-xioi)6

For spinal muscular atrophy

 

To learn more about these therapies or to submit a referral, please call us at 877.455.4822 or email us at medicalservices@emergingtherapies.com.

1 https://www. https://packageinserts.bms.com/pi/pi_breyanzi.pdf
2 https://www.us.kymriah.com/
3 https://www.tecartus.com/
4 https://www.yescarta.com/
5 https://luxturna.com/
6 https://www.zolgensma.com/

*This list only contains cell and gene therapies which may be eligible for coverage.  To be covered, any therapy must meet all the other terms and conditions applicable to coverage.  This list may be modified at any time by adding or deleting cell or gene therapies. Any such modifications will be made by updating this website page. The version of this list available on any given date is applicable to therapies which may be provided on that date.

 

© 2021 Emerging Therapy Solutions, Inc. All Rights Reserved. AP-10045v2 0221. ETS and LifeTrac are trademarks of Emerging Therapy Solutions, Inc. All other trademarks referenced herein are the property of their respective owners.